• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Our Bureau

New Delhi , Dec. 9

NICHOLAS Piramal India Ltd (NPIL) is looking at increased global penetration through a "differentiated export strategy."

This strategy envisages collaboration with large companies in those stages of the drug development process where other Indian companies are not focussed.

"Indian companies usually target the early to market segment, when drugs go off-patents. But NPIL would look at other parts of the value-chain, which would look at the drug in its pre-launch, on-patent and late to market stage. And for this the company would collaborate with large companies," Mr Ajay Piramal, Chairman of NPIL, said here today.

Mr Piramal was in the city to announce the company's tie-up with the US-based Advanced Medical Optics (AMO), a global company in ophthalmic surgical devices and eye care products, for the supply of selected components of AMO's eye care products. He also indicated that the company is likely to announce another tie-up before the end of the current fiscal.

``We have an exclusive tie-up to supply form fill and seal solution products to AMO for 60 countries," he said. The agreement is for five years, starting in January 2005 and it is expected to clock revenues of about $15 million to $25 million per year, for the next five years, he said.

Production would be done at NPIL's Pithampur facility in Madhya Pradesh and the company has invested about Rs 40 crore to upgrade this plant to meet the requirements for AMO's products.

Article E-Mail :: Comment :: Syndication

Stories in this Section
BPCL policy for crude risk management soon

Copyright © 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line